Manidipino Stada

Manidipine, the active ingredient in Manidipino Stada, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients requiring blood pressure control. GNH USA supplies Manidipino Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipino is a calcium channel blocker indicated for the management of hypertension and related blood‑pressure disorders.

- Essential hypertension: lowers both systolic and diastolic blood pressure. - Isolated systolic hypertension: reduces elevated systolic pressure. - Secondary hypertension (e.g., renovascular): assists in achieving target blood‑pressure levels.

Manidipine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and reddening of skin. - Dizziness or light‑headedness, especially on standing. - Peripheral edema: swelling of ankles or feet. - Nausea or abdominal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Myocardial infarction: rare but reported in vulnerable patients. - Angio‑edema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Manidipino, clinicians should consider several safety aspects. - Monitor blood pressure: adjust dosage to maintain target levels. - Assess renal function: use cautiously in patients with renal impairment. - Avoid abrupt discontinuation: may precipitate rebound hypertension. - Caution in elderly: increased sensitivity to hypotensive effects. - Store at room temperature: keep in the original pack, protect from moisture.

Manidipino can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other calcium channel blockers: additive hypotensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations. - Grapefruit juice: may raise systemic exposure.

Moderate Interactions (Monitor Closely):\n- Diuretics: enhanced antihypertensive response, monitor electrolytes. - Beta‑blockers: possible excessive heart‑rate reduction. - ACE inhibitors or ARBs: watch for renal function changes and potassium levels.